I agree. The reason RLFTF looks promising is that it has a drug that targets lung issues but the risk is higher because it doesn't have the broad possibilities of leronlimab along with the very high float.

I sold 4% of my CYDY at about $6.50 and put it into HGEN to hedge on covid a little but after Humanigen increased authorized shares by more than 2x and the CSO said in the last conf call that he expected "slippage" from the positive IND results I sold half my position and may sell the rest. I'm thinking about putting that money into RLFTF based on Dr Yo's analysis but am willing to wait for a dip.